India’s cough-syrup crackdown begins with tragedy but may end up reshaping how Kashmir seeks care, fights addiction, and trusts medicine itself. Mir Suneem reports.

On a winter evening in Kashmir, the local pharmacy is often busier than the nearest clinic.

A father arrives carrying a child wrapped in a woollen blanket, coughing through the cold air. A college student walks in seeking relief from a persistent throat infection. An elderly man asks for the same syrup he has used every winter for years. The pharmacist reaches toward a familiar shelf, retrieves a bottle, and the transaction is completed within minutes.

For generations, this has been one of the most ordinary scenes in Indian healthcare. 

No appointment. No waiting room. No prescription. Just a bottle.

That routine, repeated countless times across Kashmir and the rest of India, is about to change.

The Union Ministry of Health and Family Welfare has amended the Drugs Rules, 1945 through the Drugs (Fifth Amendment) Rules, 2026, removing syrup formulations from Schedule K exemptions that previously allowed easier retail sale. The amendment effectively ends the over-the-counter availability of syrup-based medicines, including many commonly used cough syrups. Pharmacies can now dispense them only against a valid prescription issued by a registered medical practitioner.

The change may appear bureaucratic on paper, but it represents one of the most consequential pharmaceutical regulations introduced in recent years. It arrives at a moment when India is grappling with questions about drug safety, pharmaceutical accountability, substance abuse and public trust in medicine itself.

And nowhere do those questions converge more sharply than in Kashmir.

The government’s decision did not emerge in isolation.

It followed years of mounting concern over the safety of cough syrups manufactured and sold in India.

The issue exploded onto the international stage in 2022 when health authorities linked Indian-manufactured cough syrups to the deaths of dozens of children in The Gambia. Investigations found contamination involving diethylene glycol and ethylene glycol—industrial chemicals that can cause acute kidney failure, neurological damage and death.

The tragedy stunned global health regulators.

For many countries, India had long been synonymous with affordable medicines and large-scale pharmaceutical manufacturing. Suddenly, questions were being asked about quality control, testing procedures and oversight mechanisms.

The scrutiny deepened when similar concerns emerged in Uzbekistan. Once again, investigators identified contamination concerns involving Indian-made cough formulations. International recalls followed. Manufacturing facilities were inspected. Regulatory agencies came under pressure.

The world had discovered a vulnerability in a system that had long been viewed as one of India’s greatest industrial successes.

Yet for some health professionals in Jammu and Kashmir, the warnings did not feel entirely new.

Years before the international controversies, the region had experienced its own painful reminder of what happens when pharmaceutical safeguards fail.

Medical experts frequently recall the deaths of children in Udhampur district during 2019 and 2020 after consumption of a contaminated cough syrup. Though the scale differed from the international tragedies, the lesson was unmistakable: weaknesses in manufacturing oversight and supply-chain monitoring could have devastating consequences.

The memory still lingers among doctors, regulators and families.

For them, the government’s latest move is not merely a response to events abroad. It is an acknowledgment of risks that have already touched Indian communities.

To understand the significance of the new rules in Kashmir, one must understand the role pharmacies play in everyday life.

Across large parts of the Valley, pharmacies function as more than retail outlets. They often serve as informal healthcare centres.

In urban areas such as Srinagar, patients can access specialists relatively easily. In remote districts, however, reaching a doctor may involve long journeys, difficult terrain and significant expenses.

The result is a culture of self-medication.

A cough is treated with a syrup recommended by a chemist. A fever is addressed with medicine purchased directly from a pharmacy. A recurring respiratory infection is managed using a product that worked previously.

The practice is not unique to Kashmir. Across India, millions rely on pharmacists as their first source of medical advice.

Sometimes it works. Sometimes it does not.

Doctors have long warned that self-medication can mask serious illnesses, delay diagnoses and expose patients to unnecessary side effects. What begins as a common cough may be asthma, pneumonia, tuberculosis or another condition requiring professional evaluation.

A bottle purchased without consultation can provide temporary relief while allowing a more serious disease to progress unnoticed.

The new prescription requirement seeks to interrupt that cycle.

Supporters argue that forcing a medical consultation before obtaining cough syrups will encourage earlier diagnosis, more appropriate treatment and better health outcomes.

Critics worry that it could create new barriers for vulnerable populations.

Both perspectives contain legitimate concerns.

A resident of central Srinagar may be able to secure a prescription with relative ease. Someone living in a remote village in Kupwara, Kishtwar, Bandipora or Rajouri may face a very different reality.

For them, what appears to policymakers as a safeguard could feel like an obstacle.

The success of the policy may therefore depend not only on regulation but also on improving access to healthcare itself.

The new rules also intersect with another issue that has transformed public-health discussions in Jammu and Kashmir: substance abuse.

Over the last decade, concern about addiction has grown steadily across the region.

Officials, healthcare providers and rehabilitation centres have repeatedly warned of increasing numbers of young people seeking treatment for substance dependence. Public conversations have focused largely on heroin and synthetic drugs, but addiction specialists note that many substance-use journeys begin elsewhere.

Sometimes they begin with medicines.

Certain cough syrups contain codeine or related opioid compounds. When used appropriately under medical supervision, they can be effective treatments. When misused, they can produce euphoric effects and lead to dependency.

Anti-drug agencies across India have documented recurring cases involving the illegal diversion and recreational consumption of codeine-based cough formulations. In several states, authorities have uncovered networks trafficking pharmaceutical products intended for legitimate medical use.

While cough syrups represent only a small fraction of overall substance abuse cases, specialists warn that their accessibility has historically made them attractive to adolescents and young adults experimenting with psychoactive substances.

Kashmir’s growing addiction challenge has intensified concern about such products.

Healthcare professionals have repeatedly questioned how easily certain medicines could be purchased without prescriptions. The new regulations directly address those concerns.

A prescription creates documentation. Documentation creates accountability. And accountability creates opportunities for surveillance and intervention.

Health authorities will be better positioned to identify unusual purchasing patterns, monitor distribution channels and investigate potential misuse.

In a region struggling to contain addiction, that may prove one of the amendment’s most important consequences.

The cough syrup sitting on a pharmacy shelf embodies a larger tension within Indian healthcare.

Convenience has always been one of its greatest strengths.

Millions of people can access medicines quickly and affordably without navigating complex healthcare systems. In a country where medical infrastructure remains unevenly distributed, that convenience has often filled critical gaps.

Yet convenience can also conceal risk.

The tragedies in The Gambia and Uzbekistan exposed vulnerabilities in pharmaceutical quality control. Cases of medicine misuse revealed weaknesses in dispensing practices. The widespread culture of self-medication highlighted shortcomings in healthcare access and public awareness.

Each controversy pointed toward the same uncomfortable reality: ease of access alone is not a substitute for safety.

The government’s latest intervention is an attempt to recalibrate that balance.

The question is whether the new equilibrium will hold.

For pharmacists, the changes will be immediate.

Retail chemists accustomed to selling cough syrups directly must now verify prescriptions and maintain stricter records. Compliance requirements are expected to increase. Regulatory inspections are likely to become more frequent.

Some pharmacy owners privately fear revenue losses. Others welcome the move, arguing that it protects legitimate businesses and discourages irresponsible sales practices. For consumers, the adjustment may be psychological as much as practical. Products that were once viewed as ordinary household remedies will now carry the formal status of prescription medicines. That shift matters.

Public perception often shapes behaviour as much as law. By requiring a doctor’s authorization, the government is sending a message that medicines are not merely consumer goods. They are clinical interventions requiring professional oversight.

Whether the public embraces that message remains to be seen.

At its core, the new regulation is about trust. Trust in manufacturers. Trust in pharmacies. Trust in regulators. Trust in the medicines themselves.

The contamination scandals that shook India over the past several years eroded that trust. Every report of a child dying after consuming a medicine intended to provide relief raised uncomfortable questions about oversight and accountability.

The prescription mandate cannot solve all those problems. It cannot guarantee flawless manufacturing. It cannot eliminate contamination. It cannot end addiction. But it can create additional layers of scrutiny in a system that many experts believe needed them.

For Kashmir, the stakes are unusually high. The region sits at the intersection of multiple public-health challenges: difficult geography, unequal healthcare access, growing substance-abuse concerns and lingering memories of pharmaceutical failures.

That makes it both vulnerable and uniquely positioned to reveal whether the reform succeeds.

The bottle that once moved quietly across pharmacy counters now carries the weight of a national debate.

For decades it represented convenience, familiarity and immediate relief.

Today it represents something different. A record. A prescription. A checkpoint between illness and medicine.

Whether that checkpoint ultimately becomes a safeguard or a burden will shape not only the future of cough syrups in Kashmir, but also the larger question of how India chooses to balance access, safety and trust in one of the world’s most complex healthcare systems. 

About the Author

Mir Suneem is a filmmaker and a postgraduate in filmmaking from Jamia Millia Islamia. With a strong grounding in film editing and narrative craft, she is drawn to stories the frame extends beyond the visible into the lived.